Madopar

Levodopa/Benserazide, the active ingredient in Madopar, is a Levodopa/Dopa decarboxylase inhibitor combination presented as an oral tablet for oral use. It treats Parkinson's disease and Parkinsonian syndrome in adults.

GNH USA supplies Madopar as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar is used in the management of movement disorders that respond to dopaminergic therapy.

- Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor. - Parkinsonian syndrome: alleviates similar motor deficits in secondary parkinsonism. - Levodopa‑responsive parkinsonism: provides symptomatic relief when dopamine deficiency is identified.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: often related to orthostatic changes. - Orthostatic hypotension: drop in blood pressure upon standing. - Headache: transient cranial discomfort. - Insomnia: difficulty initiating or maintaining sleep. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements. - Hallucinations: visual or auditory perceptual disturbances. - Severe hypotension: marked drop in blood pressure requiring medical attention. - Neuroleptic malignant syndrome: rare but life‑threatening reaction. - Cardiac arrhythmias: irregular heart rhythms. - Anaphylaxis: acute allergic reaction with airway compromise.

Before initiating therapy, clinicians should consider several safety aspects. - Monitor blood pressure: watch for orthostatic changes, especially in the elderly. - Assess psychiatric status: be alert for hallucinations or confusion. - Adjust dose in renal impairment: reduced clearance may increase exposure. - Avoid abrupt discontinuation: taper to prevent withdrawal symptoms. - Use with caution in elderly patients: increased sensitivity to side effects. - Store at room temperature: keep in the original pack, protect from moisture.

Levodopa/benserazide can interact with several medication classes.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (D2 antagonists): may diminish antiparkinsonian effect. - Iron or calcium supplements: reduce levodopa absorption.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure lowering. - Carbamazepine: may increase levodopa metabolism. - Serotonergic drugs: potential for serotonin syndrome.